3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Paraganglioma, Extra-Adrenal
2
Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Meningeal Carcinomatosis
1
Melanoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Medullary
1
Biliary Tract Neoplasms
1
Interventions
Temozolomide
405
Radiotherapy
202
Bevacizumab
157
Radiation
80
Magnetic Resonance Spectroscopy
77
Lomustine
49
Surgical Procedures, Operative
45
Carmustine
41
pembrolizumab
40
Irinotecan
38
Nivolumab
32
Specimen Handling
28
Carboplatin
27
Radiosurgery
24
Erlotinib Hydrochloride
24
Drug Therapy
23
Chemotherapy, Adjuvant
23
Radiotherapy, Intensity-Modulated
22
Cyclophosphamide
20
Aminolevulinic Acid
20
O(6)-benzylguanine
17
sargramostim
16
Radiotherapy, Conformal
15
Blood Specimen Collection
15
temsirolimus
14
Granulocyte-Macrophage Colony-Stimulating Factor
14
Everolimus
14
Vorinostat
13
Sorafenib
13
Ipilimumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
lenvatinib
×
CNS
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts